Safety of corticosteroid therapy in patients with pulmonary sarcoidosis

Conclusion: The need of alternative immunosuppressive therapy in sarcoidosis patients with lung parenchymal lesions is about 32,4 %. The study data indicate the necessity of development of new effective and safe immunosuppressive therapy in pulmonary sarcoidosis patients.

Source: European Respiratory Journal - December 6, 2017 Category: Respiratory Medicine Authors: Merenkova, I., Dziublyk, Y. Tags: Diffuse Parenchymal Lung Disease Source Type: research